Stakeholder collaboration for spinal muscular atrophy therapy development-Reference-Cited by-同舟云学术

Stakeholder collaboration for spinal muscular atrophy therapy development

Published:2017-04 Issue:4 Volume:16 Page:264
ISSN:1474-4422
Container-title:The Lancet Neurology
language:en
Short-container-title:The Lancet Neurology

Author:

Aartsma-Rus Annemieke,Balabanov Pavel,Binetti Luca,Haas Manuel,Haberkamp Marion,Mitchell Joanna,Rosa Mário Miguel,Muntoni Francesco,Finkel Richard,Mercuri Eugenio

Publisher

Elsevier BV

Subject

Clinical Neurology

Reference2 articles.

1. Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy;Straub;Lancet Neurol,2016

2. Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials;Mercuri;Neuromuscul Disord,2016

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical, immunohistochemical, and genetic characterization of splice-altering biallelic DES variants: Therapeutic implications;Human Genetics and Genomics Advances;2024-04

2. Parents as informal caregivers of children and adolescents with spinal muscular atrophy: a systematic review of quantitative and qualitative data on the psychosocial situation, caregiver burden, and family needs;Orphanet Journal of Rare Diseases;2022-07-19

3. Longitudinal natural history of type I spinal muscular atrophy: a critical review;Orphanet Journal of Rare Diseases;2020-04-05

4. A critical review of patient and parent caregiver oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in spinal muscular atrophy;Neuromuscular Disorders;2019-12

5. An observational study of functional abilities in infants, children, and adults with type 1 SMA;Neurology;2018-07-25